ArticleGenes and immunity2014
A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.
Article in Genes and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- A CD8Nature communications · 2021Trial
- Immunophenotyping challenges in the diagnosis of NK-LGLL.Blood advances · 2026Article
- Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism.Blood advances · 2025Article
- Characterization of KIRHLA · 2022Article
- Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes.HLA · 2022Article
- Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.Biomolecules · 2020Review
- Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions.Journal of virology · 2018Article
- Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile.Frontiers in immunology · 2018Article
- Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.Frontiers in immunology · 2018Article
- Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology.Immunology · 2017Review
- Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control.Scientific reports · 2017Article
- The differential impact of natural killer (NK) cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in-vitro HIV infection.Clinical and experimental immunology · 2016Article
- KIR2DS5 in the presence of HLA-C C2 protects against endometriosis.Immunogenetics · 2015Article
- A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation.Frontiers in immunology · 2015Article
- Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?Frontiers in immunology · 2015Review
- Increased frequency and function of KIR2DL1-3⁺ NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes.European journal of immunology · 2014Article
- Characterization of a weakly expressed KIR2DL1 variant reveals a novel upstream promoter that controls KIR expression.Genes and immunity · 2014Article
- Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation.European journal of immunology · 2014Article
- Activating killer cell Ig-like receptors in health and disease.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Analysis of killer cell immunoglobulin-like receptor (KIR) expression has been notoriously difficult because of the cross-reactivity of available antibodies, in particular between activating and inhibitory isoforms. We undertook a comprehensive study of available anti-KIR antibodies binding to activating KIRs (a-KIRs). Using cell lines stably transfected with a-KIRs (KIR2DS1-S5 and KIR3DS1), we confirmed documented binding specificities. In addition, we show that clones HPMA4 and 143211-previously assumed to be specific for KIR2DS1/L1 and KIR2DL1, respectively-bind KIR2DS5 and KIR2DS3 (HPMA4), and KIR2DS5 (143211). Other antibodies with previously undocumented binding were JJC11.6 (recognizing KIR2DS3) and 5.133 (recognizing all a-KIRs except KIR2DS1 and KIR2DS3). The novel KIR2DS5 reactivities were confirmed by blocking with soluble KIR-Fc fusion proteins, and by reverse transcriptase-PCR analysis of sorted primary natural killer cells. In conclusion, we show formerly undocumented binding properties of anti-KIR antibodies. These cross-reactivities should be taken into account when analyzing KIR expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.